• +1-646-491-9876
    • +91-20-67278686

    Search

    Oral Mucositis - Pipeline Review, H1 2017

    Oral Mucositis - Pipeline Review, H1 2017

    • Report Code ID: RW0001709494
    • Category Pharmaceuticals
    • No. of Pages 91
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Oral Mucositis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides an overview of the Oral Mucositis (Oncology) pipeline landscape.

    Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Oral Mucositis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Oral Mucositis (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Oral Mucositis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 2 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Oral Mucositis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Oral Mucositis (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Oral Mucositis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Oral Mucositis (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Oral Mucositis (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Oral Mucositis (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Oral Mucositis (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Oral Mucositis (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Figures
    Introduction
    Publisher Report Coverage
    Oral Mucositis - Overview
    Oral Mucositis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Oral Mucositis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Oral Mucositis - Companies Involved in Therapeutics Development
    Cellceutix Corp
    Clevexel Pharma SA
    Colby Pharmaceutical Company
    Galera Therapeutics Inc
    Humanetics Corp
    Onxeo SA
    Oragenics Inc
    Otsuka Holdings Co Ltd
    Soligenix Inc
    Spectrum Pharmaceuticals Inc
    Spherium Biomed SL
    Oral Mucositis - Drug Profiles
    AG-013 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BCD-600 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BIO-300 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brilacidin tetrahydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    clonidine hydrochloride ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CVXL-0095 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dusquetide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GC-4419 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Oral Mucositis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate SOD2 for Oral Mucositis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GM-0111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HYLP-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KIN-219 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    melatonin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pralatrexate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rebamipide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oral Mucositis - Dormant Projects
    Oral Mucositis - Discontinued Products
    Oral Mucositis - Product Development Milestones
    Featured News & Press Releases
    Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients
    Dec 12, 2016: Soligenix Announces SGX942 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
    Dec 08, 2016: Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis
    Dec 08, 2016: Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
    Nov 21, 2016: U.S. FDA Grants Fast Track Designation for the Development of Oragenics AG013 for Oral Mucositis
    Oct 26, 2016: Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications
    Oct 18, 2016: Soligenix Announces Publication of its Phase 2 Clinical Trial Results of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
    Sep 27, 2016: Galera Therapeutics Announces Presentation of One-Year Follow-up Data from a Phase 1b/2a Study of GC4419 In the Reduction of Severe Oral Mucositis
    Sep 06, 2016: Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs
    Aug 30, 2016: Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment
    Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis
    Jun 06, 2016: Soligenix Announces Presentation of Phase 2 Oral Mucositis Clinical Trial Results at the 2016 Multinational Association for Supportive Care in Cancer Conference
    Jun 06, 2016: Galera Therapeutics Announces Presentation at ASCO of Positive Results from Study of GC4419 for the Reduction of Severe Oral Mucositis
    May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol
    Apr 14, 2016: Soligenix Announces Issuance of New Patents for Dusquetide
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Oral Mucositis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Oral Mucositis - Pipeline by Cellceutix Corp, H1 2017
    Oral Mucositis - Pipeline by Clevexel Pharma SA, H1 2017
    Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1 2017
    Oral Mucositis - Pipeline by Galera Therapeutics Inc, H1 2017
    Oral Mucositis - Pipeline by Humanetics Corp, H1 2017
    Oral Mucositis - Pipeline by Onxeo SA, H1 2017
    Oral Mucositis - Pipeline by Oragenics Inc, H1 2017
    Oral Mucositis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
    Oral Mucositis - Pipeline by Soligenix Inc, H1 2017
    Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
    Oral Mucositis - Pipeline by Spherium Biomed SL, H1 2017
    Oral Mucositis - Dormant Projects, H1 2017
    Oral Mucositis - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Oral Mucositis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Oral Mucositis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Cellceutix Corp
    Clevexel Pharma SA
    Colby Pharmaceutical Company
    Galera Therapeutics Inc
    Humanetics Corp
    Onxeo SA
    Oragenics Inc
    Otsuka Holdings Co Ltd
    Soligenix Inc
    Spectrum Pharmaceuticals Inc
    Spherium Biomed SL

    Request for Sample

    Report Url http://www.reportsweb.com//oral-mucositis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//oral-mucositis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//oral-mucositis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments